XML 38 R13.htm IDEA: XBRL DOCUMENT v3.19.3
Stock Based Compensation
3 Months Ended
Sep. 30, 2019
Stock Based Compensation  
Note 7 - Stock Based Compensation

The equity incentive plan of the Company was established in February of 2017. The Board of Directors of the Company may from time to time, in its discretion grant to directors, officers, consultants and employees of the Company, non-transferable options to purchase common shares, provided that the number of options issued do not exceed 10,000,000. The options are exercisable for a period of up to 10 years from the date of the grant. The number of options to purchase common shares was increased from 5,000,000 to 10,000,000 through a consent of stockholders to amend and restate the equity incentive plan.

 

The following table reflects the continuity of stock options for the three months ended September 30, 2019:

 

A summary of stock option activity is as follows:

 

 

September 30,

2019

 

Number of options outstanding:

 

Beginning of year

 

4,598,823

 

Granted

 

-

 

Exercised, converted

 

-

 

Forfeited / exchanged / modification

 

-

 

End of period

 

4,598,823

 

Number of options exercisable at end of period

 

763,453

 

Number of options available for grant at end of period

 

4,562,408

 

Weighted average option prices per share:

 

Granted during the period

 

$

0.69

 

Exercised during the period

 

$

0.00

 

Terminated during the period

 

$

0.00

 

Outstanding at end of period

 

$

0.37

 

Exercisable at end of period

 

$

0.32

 

Stock-based compensation expense attributable to stock options was approximately $605,709 for the three-month period ended September 30, 2019. As of September 30, 2019, there was approximately $2,492,958 of unrecognized compensation expense related to unvested stock options outstanding, and the weighted average vesting period for those options was 3 years.

 

Warrants

 

At September 30, 2019, the Company had outstanding warrants to purchase the Company’s common stock which were issued in connection with multiple financing arrangements. Information relating to these warrants is summarized as follows:

 

Warrants

 

Remaining

Number

Outstanding

 

Weighted

Average

Remaining Life (Years)

 

Weighted

Average

Exercise Price

 

Warrants-Financing

 

86,957

 

3.55

 

$

1.15

 

Warrants-Issued with Convertible Notes

 

600,000

 

3.98

 

$

0.75

 

Warrants-Financing

 

 360,577

 

 4.8

 

 0.78

 

Warrants A - Financing

 

7,018,090

 

.8

 

0.16

 

Warrants B – Financing

 

28,072,364

 

4.8

 

0.16

 

Total

 

36,137,988

 

-

 

-